HLS Therapeutics (TSE:HLS) Shares Up 2.2% – Here’s What Happened

HLS Therapeutics Inc. (TSE:HLS)’s stock price traded up 2.2% during mid-day trading on Tuesday . The company traded as high as C$4.23 and last traded at C$4.20. 9,200 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 20,629 shares. The stock had previously closed at C$4.11.

HLS Therapeutics Stock Up 2.2%

The firm has a fifty day simple moving average of C$4.39 and a 200 day simple moving average of C$4.49. The company has a debt-to-equity ratio of 75.00, a quick ratio of 1.01 and a current ratio of 1.00. The company has a market cap of C$131.35 million, a PE ratio of -13.12 and a beta of -0.15.

HLS Therapeutics (TSE:HLS) last announced its quarterly earnings data on Friday, May 15th. The company reported C($0.10) earnings per share for the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%.The company had revenue of C$17.88 million for the quarter. Equities research analysts predict that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.